Philadelphia / Dublin / Buffalo / Houston / Los Angeles / Toronto / Cytarabine / Raleigh / New York / Chicago / /
Company
Fox Chase / Novartis / Astex Pharmaceuticals Inc. / Teva / Celgene / AstraZeneca / /
Country
Canada / /
Facility
Research Institute / Temple University / UT MD Anderson Cancer Center / University of Southern California / NY Presbyterian Medical Center / Princess Margaret Cancer Center / The Ohio State University / Roswell Park Cancer Institute / Fox Chase Cancer Center / University of Chicago Medical Center / Duke University Medical Center / Fort Myers / Fels Institute / /
IndustryTerm
treatment of relapsed/refractory Acute Myeloid Leukemia / /
MedicalCondition
Cancer / disease / relapsed/refractory Acute Myeloid Leukemia / /
Organization
Princess Margaret Cancer Center / The University of Chicago Medical Center / University of Southern California / Fels Institute / Cornell / Keck School of Medicine / NY Presbyterian Medical Center / Cancer Specialist and Research Institute / The Ohio State University / Columbus / Temple University / Philadelphia / Duke University Medical Center / Roswell Park Cancer Institute / /
Person
Gail J. Roboz / /
Position
Major / elacytarabine vs. investigator / /
Product
SC / /
ProvinceOrState
Texas / Pennsylvania / Illinois / Southern California / North Carolina / California / New York / /
Comparison of the Efficacy and Safety of 5-day and 10day schedules of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory Acute Myeloid Leukemia (r/r AML) Gail J. Roboz